Larimar Therapeutics (NASDAQ:LRMR) Earns Outperform Rating from Wedbush

Larimar Therapeutics (NASDAQ:LRMR)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $11.00 target price on the stock. Wedbush’s price objective suggests a potential upside of 99.28% from the company’s previous close.

A number of other equities research analysts have also issued reports on the stock. Lifesci Capital raised shares of Larimar Therapeutics to a “strong-buy” rating in a research note on Tuesday. Leerink Partners raised Larimar Therapeutics to a “strong-buy” rating in a research report on Monday, January 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Larimar Therapeutics in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $16.14.

Larimar Therapeutics Price Performance

Shares of LRMR opened at $5.52 on Wednesday. The business’s 50-day moving average is $3.53 and its 200-day moving average is $3.79. The company has a market capitalization of $456.95 million, a price-to-earnings ratio of -2.86 and a beta of 1.00. Larimar Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $6.42.

Institutional Investors Weigh In On Larimar Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in LRMR. AIGH Capital Management LLC acquired a new stake in shares of Larimar Therapeutics in the third quarter valued at about $3,230,000. Ethic Inc. acquired a new position in shares of Larimar Therapeutics during the 2nd quarter worth about $187,000. XTX Topco Ltd bought a new stake in Larimar Therapeutics during the 2nd quarter valued at approximately $484,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Larimar Therapeutics by 70.6% during the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 307,198 shares of the company’s stock valued at $888,000 after purchasing an additional 127,171 shares during the period. Finally, CWM LLC grew its holdings in Larimar Therapeutics by 205.0% in the 2nd quarter. CWM LLC now owns 32,652 shares of the company’s stock valued at $94,000 after buying an additional 21,948 shares during the last quarter. 91.92% of the stock is currently owned by institutional investors and hedge funds.

Key Larimar Therapeutics News

Here are the key news stories impacting Larimar Therapeutics this week:

• Positive Sentiment: Lifesci Capital upgraded LRMR to a “Strong-Buy” and published Q4 2025 and FY2025 EPS estimates (Q4: ($0.41); FY2025: ($1.70)), signaling analyst confidence in the company’s outlook and supporting demand for the shares. MarketBeat Lifesci Note
• Positive Sentiment: Citigroup raised its price target to $14 (buy), and Wedbush reaffirmed an outperform rating with an $11 target — both represent substantial upside vs. the current level and underpin bullish analyst sentiment. Benzinga
• Positive Sentiment: Unusually large call-option activity occurred (several thousand calls bought), suggesting short-term bullish positioning by traders and contributing to intraday spikes before the equity raise announcement. (No direct article link provided)
• Positive Sentiment: Coverage and commentary explaining the intraday rally were published (coverage noted a ~22% intraday rise before the selloff), which can attract momentum buyers and increased attention. AAII Article
• Neutral Sentiment: The company initially announced a proposed $75M underwritten offering (preliminary press release) — this first filing signaled capital raise intent before the deal was upsized. GlobeNewswire – Proposed Offering
• Negative Sentiment: Larimar priced an upsized underwritten public offering of 20,000,000 shares at $5.00 per share (gross proceeds ~$100M) and granted a 30-day option for an additional 3,000,000 shares — direct dilution and increased share supply are the main catalysts pressuring the stock. GlobeNewswire – Priced Offering

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc is based in Bala Cynwyd, Pennsylvania.